Form 4: Cassava Sciences CEO Remi Barbier Granted Stock Options

Remi Barbier, President and CEO of Cassava Sciences, was granted stock options for 50,000 shares on May 20, 2024.

Summary

• Remi Barbier, the President and CEO of Cassava Sciences, received stock options to purchase 50,000 shares of common stock on May 20, 2024.
• The exercise price of these options is $22.10 per share.
• The options vest over four years, with 1/48th of the options vesting each month, beginning May 20, 2024.
• The options expire on May 20, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard executive compensation practice, neither overly positive nor negative.

Positives

• The granting of stock options to the CEO aligns his interests with those of the shareholders, incentivizing him to increase the company's value.

Risks

• The vesting schedule means the CEO only benefits if he remains with the company for a significant period, which may or may not align with the company's long-term strategy.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Companies like Biogen, Amgen, and Gilead Sciences also utilize stock options to incentivize their executives.
• The vesting schedule of four years is typical for such grants.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the CEO to increase shareholder value.
• Employees may see it as a sign of confidence in the company's future.

Key Dates